Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (¹⁷⁷ Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.

ABSTRACT:

Lessons learned

Hyperfractionation of lutetium-177 (¹⁷⁷ Lu)-J591 for patients with metastatic castration-resistant prostate cancer did not appear to have any additional advantage over the single dose ¹⁷⁷ Lu-J591 or fractionated two-dose ¹⁷⁷ Lu-J591 therapy. Definite conclusions were challenging because of the small sample size of this study, and so further studies are needed to evaluate the viability of the hypothesis. On the basis of available data, a registration study of ¹⁷⁷ Lu-J591 (also known as TLX591) is planned and will use the two-dose fractionation schedule (Telix Pharma Q3 2019 update https://telixpharma.com/news-media/).

Background

Phase I and II single-dose studies of lutetium-177 (¹⁷⁷ Lu)-J591, a radio-labe

SUBMITTER: Niaz MJ 

PROVIDER: S-EPMC7288642 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature